Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
![GlobeNewswire](../../../Content/images/providers/GN.png)
Gyre Therapeutics, Inc. (GYRE)
Company Research
Source: GlobeNewswire
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that China’s National Medical Products Administration (“NMPA”) has approved Gyre Pharmaceuticals’ (Gyre’s indirectly controlled subsidiary) avatrombopag maleate tablets for the treatment of thrombocytopenia (“TP”) associated with chronic liver disease (“CLD”) in adult patients undergoing elective diagnostics procedures or therapy. TP is the most common hematologic complication in patients with CLD and can be life threatening in severe cases. “The approval of avatrombopag maleate tablets by the NMPA represents an important milestone for Gyre as we expand our rare disease product lines and build our presence in developing treatments for patients with CLD,” said Han Ying, Ph.D., CEO of Gyre Therapeutics. “We are eager to launch avatrombopag i
Show less
Read more
Impact Snapshot
Event Time:
GYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GYRE alerts
High impacting Gyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GYRE
News
- Estimating The Intrinsic Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE) [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics Announces Publication in Journal of Gastroenterology and HepatologyGlobeNewswire
- Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial HypertensionGlobeNewswire
- Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® IndexesGlobeNewswire
- Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
GYRE
Sec Filings
- 7/5/24 - Form 8-K
- 7/3/24 - Form 144
- 7/2/24 - Form 144
- GYRE's page on the SEC website